Actively Recruiting
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Led by Scandinavian Critical Care Trials Group · Updated on 2025-07-03
5800
Participants Needed
2
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
CONDITIONS
Official Title
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of sepsis or septic shock defined by suspected or documented infection and acute increase of 2 or more points in SOFA score
- Critical illness requiring at least one of the following: invasive mechanical ventilation, non-invasive ventilation, continuous use of CPAP for hypoxia, oxygen supplementation with flow of 10 litres/minute or more, or continuous infusion of vasopressor or inotrope
- Clinical indication for empirical treatment with either meropenem or piperacillin/tazobactam
You will not qualify if you...
- Intravenous treatment with meropenem or piperacillin/tazobactam for more than 24 hours before screening
- Fertile women under 60 years with known pregnancy or positive pregnancy test
- Known allergy or hypersensitivity to beta-lactam antibiotics
- Suspected or documented central nervous system infection
- Infection or colonization with bacteria resistant to meropenem or piperacillin/tazobactam within the last 3 months
- Current or planned use of valproate within 30 days from randomisation
- Enrollment in another interventional trial that conflicts with this study
- Previous participation in this EMPRESS trial
- Expected inability to provide informed consent after inclusion
- Patient under coercive measures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Rigshospitalet
Copenhagen, København Ø, Denmark, 2100
Not Yet Recruiting
2
Rigshospitalet
Copenhagen, Denmark
Actively Recruiting
Research Team
M
Morten H Møller, MD, Professor, PhD
CONTACT
N
Nick Meier, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here